Xtant Medical Holdings Inc. Common Stock
XTNTUnited States
5 filed reports · 236 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 827 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 578 | Dec 2025 |
Financial data
236 concepts · 1,405 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial232 concepts · 1,306 facts · Mar 2024 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value12 · Mar 2024 to Jun 2026
- Net income loss12 · Mar 2024 to Jun 2026
- Other comprehensive income loss foreign currency transaction and translation adjustment net of tax12 · Mar 2024 to Jun 2026
- Stockholders equity (US GAAP)12 · Mar 2024 to Jun 2026
- Cash and cash equivalents at carrying value11 · Jun 2024 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents11 · Jun 2024 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations11 · Jun 2024 to Jun 2026
- Comprehensive income net of tax11 · Jun 2024 to Jun 2026
- Cost of goods and services sold (US GAAP)11 · Jun 2024 to Jun 2026
- Depreciation11 · Jun 2024 to Jun 2026
- Foreign currency transaction gain loss unrealized11 · Jun 2024 to Jun 2026
- General and administrative expense (US GAAP)11 · Jun 2024 to Jun 2026
- Gross profit (US GAAP)11 · Jun 2024 to Jun 2026
- Income tax expense benefit11 · Jun 2024 to Jun 2026
- Interest expense nonoperating11 · Jun 2024 to Jun 2026
- Nonoperating income expense11 · Jun 2024 to Jun 2026
- Operating expenses (US GAAP)11 · Jun 2024 to Jun 2026
- Operating income loss11 · Jun 2024 to Jun 2026
- Other nonoperating income expense11 · Jun 2024 to Jun 2026
- Research and development expense11 · Jun 2024 to Jun 2026
- Restricted cash and cash equivalents11 · Jun 2024 to Jun 2026
- Revenue11 · Jun 2024 to Jun 2026
- Selling and marketing expense (US GAAP)11 · Jun 2024 to Jun 2026
- Share based compensation11 · Jun 2024 to Jun 2026
Product2 concepts · 72 facts · Jun 2024 to Jun 2026
- Revenue49 · Jun 2024 to Jun 2026
- Percentage of total revenue23 · Jun 2024 to Jun 2026
Geography2 concepts · 27 facts · Jun 2024 to Jun 2026
- Revenue23 · Jun 2024 to Jun 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest4 · Dec 2024 to Dec 2025
Segments
99 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service6 members · 72 facts
- Orthobiologics20 · Jun 2024 to Jun 2026
- Spinal Implant20 · Jun 2024 to Jun 2026
- License Revenue11 · Dec 2024 to Dec 2025
- Product11 · Jun 2024 to Jun 2026
- License6 · Dec 2024 to Dec 2025
- Bill And Hold Transactions4 · Sep 2025 to Jun 2026
Statement geographical3 members · 27 facts
- US13 · Jun 2024 to Jun 2026
- Non Us12 · Sep 2024 to Jun 2026
- Rest Of World2 · Jun 2024 to Jun 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Nov 2025 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 11, 2026
- FY2026 Q1May 13, 2026
- FY2025 Q4Mar 31, 2026
- FY2025 Q3Nov 11, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.